Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2025-522291-83-00 | EU Trial (CTIS) Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled in the study.
The study will consist of 3 periods:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DFL24498 | Experimental | Participants will be administered with DFL24498 eye drops in both eyes. |
|
| Vehicle | Placebo Comparator | Participants will be administered with vehicle eye drops in both eyes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DFL24498 | Drug | DFL24498 will be instilled in each eye for 12 Weeks. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS). | The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point. | Baseline and at Week 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline at week 6 in corneal epithelial fluorescein staining, scored by modified Oxford scale, in the study eye. | Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. Examination will be performed at the slit-lamp using blue (cobalt) light. Corneal fluorescein staining will be graded according to the modified Oxford scale (7-point scale: 0, 0.5. 1, 2, 3, 4, 5). |
Not provided
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
Men or women aged ≥ 18 and ≤ 65 years of age.
Diagnosis of AKC in both eyes, including the presence or medical history of the following:
Ocular itching of at least 50 as assessed by VAS scale.
Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.
A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).
If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.
Exclusion Criteria:
Participants will be excluded if any of the following criteria apply:
Note: Additional protocol defined Inclusion/Exclusion criteria apply
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI) | Contact | +39 02 583 831 |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bowden Eye Associates - Southside Location | Recruiting | Jacksonville | Florida | 32256 | United States | |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Vehicle |
| Drug |
Vehicle eye drops without active drug will be instilled in each eye for 12 Weeks. |
|
| dexamethasone sodium phosphate (DSP) ophthalmic solution | Drug | Rescue medication may be administered as required at the Investigator discretion. |
|
| Baseline and at Week 6 |
| Change from baseline at week 6 in bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100), in the study eye. | Bulbar conjunctival redness will be assessed at the slit-lamp examination using white light prior to vital dye instillation and graded according to the VBR 10 scale. | Baseline and at Week 6 |
| Change from baseline over time in ocular itching score assessed by VAS. | The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point. | Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16 |
| Change from baseline over time in ocular symptoms of itching, tearing, discomfort, mucous discharge, and photophobia on a 4-point scale (0 to 3). | Ocular symptoms are assessed using a 4-point severity scale ranging from 0 (none) to 3 (severe). Five ocular symptoms, itching, tearing, ocular discomfort (including burning, stinging, and foreign body sensation), mucous discharge, and photophobia are evaluated in the study eye. A composite symptom score is described in calculated at screening and Baseline by summing the individual symptom scores, resulting in a total score range of 0 to 15, with higher scores indicating greater symptom severity. | Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16 |
| Change from baseline over time in corneal fluorescein staining (modified Oxford scale) in the study eye. | Corneal fluorescein staining modified Oxford scale (0-5) as per corneal dot count in each eye. | Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16 |
| Change from baseline over time in bulbar conjunctival hyperemia assessed by VBR 10 scale (0 to 100) in the study eye. | Bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100). | Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16 |
| Change from baseline over time in signs of tarsal papillary reaction, corneal neovascularization, cicatrizing conjunctivitis and blepharitis on a 4-point scale (0 to 3) in the study eye. | Change in signs on a 4-point scale (0 to 3) in the study eye. | Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16 |
| Change from baseline at week 6 and 12 in the QoL scores assessed by the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ-S) | Standardized Rhinoconjunctivitis QoL Questionnaire (RQLQ[S]) is a validated questionnaire that assesses QoL specifically in patients with rhinoconjunctivitis. There are 28 questions, which are categorized under 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Each question is scored on a 7-point scale from no impairment (score 0) to severe impairment (score 6). | Baseline and at Week 6 and Week 12. |
| Patient Global Impression of Change (PGIC) at week 6 and week 12. | PGIC is a short questionnaire used to assess how a participant perceives changes in their condition following treatment, on a scale ranging from 1 to 7. | At week 6 and week 12. |
| Number of Participants receiving rescue medication over time after week 6 | Participants who received rescued medication over time after week 6 (visit 4). | Week 6 to Week 12 |
| Number of participants with treatment-emergent adverse events and serious adverse events (SAEs) | Any adverse events occurring or worsening after the first administration of investigational product is classified as "treatment-emergent" adverse events and does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important. | Up to Week 16 |
| Change from baseline over time in best corrected distance visual acuity (BCDVA) in each eye. | Best corrected visual acuity (BCDVA) is determined by careful refraction according to the standard protocol for refraction. BCDVA is measured by Early Treatment of Diabetic Retinopathy Study chart. | Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16 |
| Change from baseline at week 12 in corneal endothelial cell density in each eye (only at selected sites that have the required equipment). | Corneal central region endothelial cell density will be determined for each eye using specular microscopy and expressed as the number of cells/mm2 using the Cell Density readout provided by the software. | Baseline and at week 12 |
| Change from baseline at week 12 in dilated fundus exam in each eye (proportion of participants with vitritis, retinal or vitreal hemorrhages, increase in cup-to-disc ratio, retinal or posterior vitreal detachment, retinal tears, or maculopathy). | After specular microscopy, mydriatic drops will be instilled in both eyes and once adequate dilation is achieved, a fundal exam shall be performed to examine the vitreous, retina, and optic nerve. | Baseline and at week 12 |
| Change from baseline over time in intraocular pressure in each eye. | IOP will be assessed by applanation tonometry for each eye and will be measured in mmHg. | Baseline and at Week 6 and Week 12 |
| Number of participants discontinued due to tolerability during the treatment period | Treatment discontinuation rate due to tolerability. | Baseline to week 12 |
| University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute |
| Recruiting |
| Miami |
| Florida |
| 33136 |
| United States |
| Clayton Eye Clinical Research | Recruiting | Morrow | Georgia | 30260 | United States |
| Ophthalmology Associates | Recruiting | St Louis | Missouri | 63131 | United States |
| NYU Langone Health - Eye Center | Recruiting | New York | New York | 10017 | United States |
| Duke Eye Center - Ophthalmology | Recruiting | Durham | North Carolina | 27710 | United States |
| Total Eye Care, PA | Recruiting | Memphis | Tennessee | 38119 | United States |
| Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology | Recruiting | Houston | Texas | 77030 | United States |
| IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia | Recruiting | Bologna | 40138 | Italy |
| Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti | Recruiting | Chieti | 66100 | Italy |
| Azienda Ospedaliero Universitaria Careggi | Recruiting | Florence | 50134 | Italy |
| Fondazione Policlinico Universitario Campus Bio-Medico | Recruiting | Roma | 00128 | Italy |
| AOU Policlinico Umberto I | Recruiting | Roma | 00161 | Italy |
| Azienda Ospedaliera Universitaria Integrata Verona | Recruiting | Verona | 37134 | Italy |
| METAVISION ARRUZAFA S.L. (Hospital Arruzafa) | Recruiting | Córdoba | 14012 | Spain |
| Miranza Galicia | Recruiting | Santiago de Compostela | 15706 | Spain |
| Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM) | Recruiting | Valencia | 46015 | Spain |
| OBA - Universidad de Valladolid | Recruiting | Valladolid | 47011 | Spain |
| Hospital Universitario Miguel Servet | Recruiting | Zaragoza | 50009 | Spain |
| ID | Term |
|---|---|
| D000092122 | Bronchiolitis Obliterans Syndrome |
| ID | Term |
|---|---|
| D000092124 | Organizing Pneumonia |
| D001989 | Bronchiolitis Obliterans |
| D001988 | Bronchiolitis |
| D001991 | Bronchitis |
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D006086 | Graft vs Host Disease |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C004180 | dexamethasone 21-phosphate |
| D009883 | Ophthalmic Solutions |
| ID | Term |
|---|---|
| D019999 | Pharmaceutical Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
| D045506 | Therapeutic Uses |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D020313 | Specialty Uses of Chemicals |
Not provided
Not provided